Effects of Rosiglitazone on Inflammation in Otsuka Long-Evans Tokushima Fatty Rats

다국어 초록 (Multilingual Abstract)

Background: Inflammation plays a role in the response to metabolic stress in type 2 diabetes. However, the effects of rosiglitazone on inflammation of skeletal muscle have not been fully examined in type 2 diabetes.
Methods: We investigated the effects of the insulin-sensitizing anti-diabetic agent, rosiglitazone, on the progression of skeletal muscle inflammation in Otsuka Long-Evans Tokushima Fatty (OLETF) type 2 diabetic rats. We examined the expression of serologic markers (serum glucose, insulin and free fatty acid) and inflammatory cytokines (tumor-necrosis factor-α, interleukin [IL]-1β and IL-6) in OLETF rats from early to advanced diabetic stage (from 28 to 40 weeks of age).
Results: Serum glucose and insulin concentrations were significantly decreased in rosiglitazone-treated OLETF rats compared to untreated OLETF rats. Rosiglitazone treatment significantly decreased the concentrations of serum inflammatory cytokines from 28 to 40 weeks of age. The mRNA expression of various cytokines in skeletal muscle was reduced in rosiglitazone-treated OLETF rats compared with untreated OLETF rats. Furthermore, rosiglitazone treatment resulted in the downregulation of ERK1/2 phosphorylation and NF-κB expression in the skeletal muscle of OLETF rats.
Conclusion: These results suggest that rosiglitazone may improve insulin sensitivity with its anti-inflammatory effects on skeletal muscle.

참고문헌 (Reference)

1 Plomgaard P, "Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation" 54 : 2939-2945, 2005

2 Sethi JK, "The role of TNF alpha in adipocyte metabolism" 10 : 19-29, 1999

3 Ricote M, "The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation" 391 : 78-82, 1998

4 Saghizadeh M, "The expression of TNF alpha by human muscle: relationship to insulin resistance" 97 : 1111-1116, 1996

5 Kawano K, "Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain" 41 : 1422-1428, 1992

6 Yuan M, "Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta" 293 : 1673-1677, 2001

7 Mishima Y, "Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with type 2 diabetes mellitus" 52 : 119-123, 2001

8 Sriwijitkamol A, "Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training" 55 : 760-767, 2006

9 Kim JK, "Prevention of fat-induced insulin resistance by salicylate" 108 : 437-446, 2001

10 Rasouli N, "Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue" 288 : 930-934, 2005

11 Delerive P, "Peroxisome proliferator-activated receptors in inflammation control" 169 : 453-459, 2001

12 Jiang C, "PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines" 391 : 82-86, 1998

13 Staels B, "Metformin and pioglitazone: Effectively treating insulin resistance" 22 (22): 27-37, 2006

14 Bouzakri K, "MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance" 282 : 7783-7789, 2007

15 Ghanim H, "Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics" 91 : 3553-3558, 2006

16 Cai D, "Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB" 11 : 183-190, 2005

17 Shoelson SE, "Inflammation and insulin resistance" 116 : 1793-1801, 2006

18 Friedman JE, "Increased skeletal muscle tumor necrosis factor-alpha and impaired insulin signaling persist in obese women with gestational diabetes mellitus 1 year postpartum" 57 : 606-613, 2008

19 Hotamisligil GS, "Increased adipose tissue expression of tumor necrosis factor- alpha in human obesity and insulin resistance" 95 : 2409-2415, 1995

20 Hotamisligil GS, "IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance" 271 : 665-668, 1996

21 Mohanty P, "Evidence for a potent antiinflammatory effect of rosiglitazone" 89 : 2728-2735, 2004

22 Winkler G, "Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in type 2 diabetics and patients with android type obesity" 42 : 169-174, 1998

23 Donath MY, "Cytokines and beta-cell biology: from concept to clinical translation" 29 : 334-350, 2008

24 Rohl M, "Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance" 113 : 474-481, 2004

25 Ahima RS, "Adipose tissue as an endocrine organ" 11 : 327-332, 2000

26 Nagaraju K, "A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli" 113 : 407-414, 1998

27 Su CG, "A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response" 104 : 383-389, 1999